Activities

Our research focuses on mitochondria from human and parasitic organisms such as nematodes (e.g., Ascaris suum) and protozoa (e.g., Trypanosoma cruzi, Trypanosoma brucei, Plasmodium falciparum, Cryptosporidium spp.). Leveraging insights from these studies, we aim to develop novel strategies, such as the use of 5-aminolevulinic acid, to combat other pathogens, including SARS-CoV-2. Additionally, we have identified excitatory amino acids as potential contributors to Nodding Syndrome in East Africa, with plans for future verification studies in endemic regions. Our research on Neglected Tropical Diseases (NTDs), with special focus on Chagas disease, prevalent in Latin America and caused by T. cruzi, aimed to understand the parasite adaptation within the host, disease progression, and metabolic interactions between host and parasite. Since 2023, we have collaborated with Brazil Research Station to study the current situation of infectious diseases in South America and to develop new diagnostic methods and drug candidates.
In addition to the trypanosomatid parasites as one of our research target organisms, we are also studying other pathogens and model organisms. This includes parasites like Eimeria tenella and Theileria spp., worms like Anisakis spp., Haemonchus contortus, and Fasciola spp., and bacteria such as Mycobacterium spp. (tuberculosis), Helicobacter pylori, Campylobacter jejuni, and Escherichia coli to understand their central metabolism and their mechanism of adaptation to survive within host harsh environment.
Our activities are supported by research grants acquired from KAKENHI（MEXT）, AMED, GHIT and Private Companies.